ESR1 and breast cancer: Both luminal A and luminal B breast cancer are likely to benefit from endocrine therapy, and patients with luminal A breast cancer have a better prognosis compared to luminal B. HER2-positive subtype is ER/PR-negative and HER2-positive, with a diagnostic rate of approximately 13−15%.